![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.biopharmadive.com/news/fda-metformin-ndma-contamination/578771/
https://www.prnewswire.com/news-releases/fda-alerts-patients-and-health-care-professionals-to-nitrosamine-impurity-findings-in-certain-metformin-extended-release-products-301067454.html
https://www.raps.org/news-and-articles/news-articles/2020/4/fda-seeks-withdrawal-of-heartburn-drugs-due-to-new
https://www.pharmacompass.com/pdf/news/glenmark-pharmaceuticals-inc-usa-voluntarily-recalls-all-unexpired-lots-of-its-ranitidine-1576662691.pdf
https://www.fox10phoenix.com/news/fda-warns-of-carcinogen-found-in-diabetes-drugs-outside-of-us
https://www.in-pharmatechnologist.com/Article/2019/12/09/Impurities-discovered-in-metformin
https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-ranitidine-150mg-10ml-oral-solution-el-19-a-29
https://www.in-pharmatechnologist.com/Article/2019/10/24/Sanofi-and-Dr-Reddy-s-initiate-ranitidine-recall
https://www.fiercepharma.com/manufacturing/aurobindo-chalks-up-new-fda-manufacturing-concerns
https://www.fiercepharma.com/manufacturing/fda-cites-solvent-recovery-firm-as-player-valsartan-mess
https://www.in-pharmatechnologist.com/Article/2019/08/14/The-sartan-saga-Recapping-the-recalls
https://www.raps.org/news-and-articles/news-articles/2019/8/ndea-and-ndma-impurities-another-indian-manufactu
https://www.raps.org/news-and-articles/news-articles/2019/7/fda-sends-warning-letters-to-aurobindo-api-repack?feed=Regulatory-Focus
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-8-2019-1557294096.pdf
https://www.pharmacompass.com/pdf/news/updated-torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-of-losartan-potassium-tablets-1555650822.pdf
https://www.raps.org/news-and-articles/news-articles/2019/3/to-prevent-losartan-shortages-fda-allows-higher-i
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69328a-eng.php
https://www.pharmacompass.com/pdf/news/american-health-packaging-issues-voluntary-nationwide-recall-of-valsartan-tablets-1552113034.pdf
https://www.in-pharmatechnologist.com/Article/2019/03/04/Macleods-and-Camber-issues-recall-on-Losartan-tablets
https://www.pharmacompass.com/pdf/news/aurobindo-pharma-usa-inc-recall-expansion-of-38-lots-of-amlodipine-valsartan-tablets-usp-1551508583.pdf
https://www.cnbc.com/2019/03/01/reuters-america-fda-finds-new-cancer-causing-impurity-in-blood-pressure-pills.html
https://www.pharmacompass.com/pdf/news/macleods-pharmaceuticals-issues-voluntary-nationwide-consumer-level-recall-of-one-lot-blm-715a-of-losartan-potassiumhydrochlorothiazide-combination-tablets-100mg25mg-1551155408.pdf
https://www.edqm.eu/en/news/update-edqm-review-cep-applications-sartan-substances-4-february-2019
https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm?utm_campaign=UPDATE%20on%20angiotensin%20II%20receptor%20blocker%20%28ARB%29%20recalls%3A%20Torrent%20further%20expands&utm_medium=email&utm_source=Eloqua
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-23-2019-1548227584.pdf
https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm?utm_campaign=UPDATE%20on%20angiotensin%20II%20receptor%20blocker%20%28ARB%29%20recalls%3A%20FDA%20alerts%20patients%20and%20health%20care&utm_medium=email&utm_source=Eloqua#interimlimits
https://www.edqm.eu/en/news/update-review-cep-applications-sartans-18-january-2019
https://www.raps.org/news-and-articles/news-articles/2019/1/eu-regulatory-roundup-uk-nhs-calls-for-changes-to?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2010%20January
https://www.dnaindia.com/business/report-a-wave-of-drug-recalls-hits-indian-pharma-firms-in-us-2705817
https://www.pharmacompass.com/pdf/news/torrent-pharmaceuticals-limited-expands-voluntary-nationwide-recall-of-losartan-potassium-tablets-1546602181.pdf
https://assets.publishing.service.gov.uk/media/5c2df2fee5274a65a26f4b71/EL__19__A_01_Final.pdf
https://www.gov.uk/government/news/irbesartan-blood-pressure-and-heart-medication-recalled-from-pharmacies-by-mhra
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-usa-recalls-80-lots-of-blood-pressure-drug-from-america/articleshow/67335904.cms
https://www.pharmacompass.com/pdf/news/torrent-pharmaceuticals-recalls-losartan-potassium-tablets-1545466699.pdf
https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=11192018103541
https://www.fiercepharma.com/manufacturing/litigation-mounts-over-contaminated-blood-pressure-meds
https://www.reuters.com/article/us-mylan-nl-valsartan-united-states/mylan-to-recall-all-batches-of-blood-pressure-medicine-valsartan-in-u-s-idUSKBN1O324E
https://www.pharmacompass.com/pdf/news/mylan-expands-voluntary-nationwide-recall-of-valsartan-tablets-due-to-trace-ndea-1544072295.pdf
https://www.gov.uk/government/news/mhra-recalls-valsartan-blood-pressure-and-heart-medication-from-pharmacies
https://www.fiercepharma.com/manufacturing/valsartan-recall-expands-to-mylan-teva-products
https://www.pharmacompass.com/pdf/news/mylan-valsartan-medications-voluntarily-recalled-due-to-an-impurity-1543564074.pdf
https://www.reuters.com/article/us-teva-pharm-ind-recall/teva-to-recall-certain-blood-pressure-medicine-in-u-s-idUSKCN1NW2HN
https://www.fiercepharma.com/manufacturing/valsartan-recall-expands-to-mylan-teva-products
https://www.swissmedic.ch/swissmedic/en/home/news/mitteilungen/analysenderijmjuli2018zurueckgerufenenvalsartan-chargen.html